This Article Full Text Full Text (PDF) All Versions of this Article: 112/9/1296    most recent CIRCULATIONAHA.104.531582v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Austin, P. C. Articles by Mamdani, M. M. Search for Related Content PubMed PubMed Citation Articles by Austin, P. C. Articles by Mamdani, M. M. Related Collections Health policy and outcome research Cardiovascular Pharmacology Primary prevention Secondary prevention

(Circulation. 2005;112:1296-1300.)
© 2005 American Heart Association, Inc.

Health Services and Outcomes Research

Impact of the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22/Reversal of Atherosclerosis With Aggressive Lipid Lowering Trials on Trends in Intensive Versus Moderate Statin Therapy in Ontario, Canada

From the Institute for Clinical Evaluative Sciences (P.C.A., M.M.M.), Department of Public Health Sciences (P.C.A.), Faculty of Pharmacy (M.M.M.), and Department of Health Policy, Management and Evaluation (P.C.A., M.M.M.), University of Toronto.

Correspondence to Dr Peter C. Austin, Institute for Clinical Evaluative Sciences, G1 06, 2075 Bayview Ave, Toronto, Ontario, M4N 3M5, Canada. E-mail peter.austin{at}ices.on.ca

Received December 22, 2004; revision received May 26, 2005; accepted June 2, 2005.

Background— In March 2004, the Reversal of Atherosclerosis With Aggressive Lipid Lowering (REVERSAL) trial demonstrated that intensive lipid-lowering therapy (atorvastatin 80 mg/d) reduced progression of coronary atherosclerosis compared with moderate lipid-lowering therapy (pravastatin 40 mg/d). The following month, the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 (PROVE IT–TIMI 22) study demonstrated the superiority of intensive (atorvastatin 80 mg/d) versus moderate (pravastatin 40 mg/d) lipid-lowering therapy for reducing death or cardiovascular events in patients suffering from an acute coronary syndrome. We sought to determine the impact of these 2 trials on trends in intensive versus moderate statin therapy in Ontario, Canada.

Methods and Results— This is a retrospective time-series analysis of statin prescribing between June 1997 and September 2004 in Ontario, Canada, for all residents age 65 years and older. The publication of the PROVE IT–TIMI 22 and REVERSAL trials was associated with a sustained and statistically significant increase in the number of prescriptions dispensed for atorvastatin 80 mg (range, 272 to 635 additional prescriptions per month), whereas the number of prescriptions filled for pravastatin 40 mg did not change. Similarly, it resulted in a temporal increase in the relative market share of atorvastatin at a dose of 80 mg versus that of atorvastatin at a dose of 40 mg. However, the proportion of simvastatin prescriptions for 80 mg relative to 40 mg did not change over time, implying a drug-specific effect rather than a class effect in prescribing practice.

Conclusions— The publication of the PROVE IT–TIMI 22 and REVERSAL trials resulted in a significant sustained increase in the use of intensive compared with moderate statin therapy. This shift was evident primarily in an increased use of high-dose atorvastatin and did not appear to be generalizable to other statins.

Key Words: cholesterol • drugs • lipids • pharmacology • trials

This article has been cited by other articles:

				N. K Choudhry, B. Zagorski, J. Avorn, R. Levin, K. Sykora, A. Laupacis, and M. Mamdani Comparison of the Impact of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management Trial on Prescribing Patterns: A Time-Series Analysis Ann. Pharmacother., November 1, 2008; 42(11): 1563 - 1572. [Abstract] [Full Text] [PDF]

				N. J. Leeper, R. Ardehali, E. M. deGoma, and P. A. Heidenreich Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival Circulation, August 7, 2007; 116(6): 613 - 618. [Abstract] [Full Text] [PDF]

				N. K Choudhry, R. Levin, and W. C Winkelmayer Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice Heart, August 1, 2007; 93(8): 945 - 951. [Abstract] [Full Text] [PDF]

				C. P. Cannon, B. A. Steinberg, S. A. Murphy, J. L. Mega, and E. Braunwald Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy J. Am. Coll. Cardiol., August 1, 2006; 48(3): 438 - 445. [Abstract] [Full Text] [PDF]

				R. P. Giugliano and E. Braunwald The Year in Non-ST-Segment Elevation Acute Coronary Syndromes J. Am. Coll. Cardiol., July 18, 2006; 48(2): 386 - 395. [Full Text] [PDF]

				P. C Austin, M. M Mamdani, and D. N Juurlink How Many "Me-Too" Drugs Are Enough? The Case of Physician Preferences for Specific Statins Ann. Pharmacother., June 1, 2006; 40(6): 1047 - 1051. [Abstract] [Full Text] [PDF]

				M. O'Donoghue, D. A. Morrow, M. S. Sabatine, S. A. Murphy, C. H. McCabe, C. P. Cannon, and E. Braunwald Lipoprotein-Associated Phospholipase A2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) Trial Circulation, April 11, 2006; 113(14): 1745 - 1752. [Abstract] [Full Text] [PDF]